Patients with germline PALB2 mutation may be sensitive to drugs that target DNA repair mechanisms like cisplatin13 or PARP inhibitors, which are being tested in clinical trials in various tumor types including pancreatic cancers14,15. This evidence concerns the gene PALB2 and neoplasm.